GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Shandong Sito Bio-technology
Who owns Shandong Sito Bio-technology Co., Ltd.?
Shandong Sito Bio-technology listed on ChiNext in January 2017, marking its shift from regional fermentation specialist to a global biotech supplier. Ownership affects R&D focus, supply-chain resilience and strategic investments. The Ma family retains significant influence amid rising institutional stakes.
Ownership remains concentrated with founding stakeholders and growing institutional investors, shaping long-term capital allocation and governance priorities. See Shandong Sito Bio-technology Porter's Five Forces Analysis for product and market context.
Who Founded Shandong Sito Bio-technology?
Founders and Early Ownership of Shandong Sito Bio-technology were dominated by Ma Yantao and his family, who seeded the company in 2010 to build fermentation facilities focused on steroid intermediates.
Founder profile
Ma Yantao held a background in chemical engineering and industrial management and provided the strategic direction at founding.
Initial capital
Seed funding came from Ma and immediate family members to finance fermentation and production capacity in Shandong.
Equity concentration
Early ownership was founder-centric, with Ma’s direct and indirect holdings often cited at over 60%.
Investment vehicle
Holdings were structured via Shandong Runze Investment Co., Ltd., which served as the primary investment vehicle for the founders.
Financing approach
No major early VC rounds; growth relied on internal accruals and local credit facilities to avoid equity dilution.
Strategic focus
The founder-centric model prioritized long-term asset growth and allowed rapid pivot to microbial AD production.
Early governance emphasized tight control to manage biotech R&D risk, with corporate decisions reflecting the Ma family’s priorities rather than external investor pressure; see Mission, Vision & Core Values of Shandong Sito Bio-technology for related corporate context: Mission, Vision & Core Values of Shandong Sito Bio-technology
Key facts on founders and early ownership
Concise ownership and founding details relevant to Shandong Sito Bio-technology ownership and corporate structure.
- Founder: Ma Yantao, chemical engineering and industrial management background
- Primary holding vehicle: Shandong Runze Investment Co., Ltd.
- Founder-controlled stake: commonly reported at over 60% when including indirect holdings
- Early funding: family seed capital, internal accruals, and local credit (no early VC)
Complete Shandong Sito Bio-technology Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Shandong Sito Bio-technology’s Ownership Changed Over Time?
Key events shaping Shandong Sito Bio-technology ownership include the 2017 IPO that introduced thousands of public shareholders, post-IPO private placements attracting private equity, and a 2024–2025 operational recovery that drew institutional investors and strengthened the founders’ control position.
| Stakeholder | Approx. Ownership | Notes |
|---|---|---|
| Shandong Runze Investment Co., Ltd. | 26.54% | Primary vehicle for the Ma family’s control; largest shareholder |
| Ma Yantao (direct) | 12.82% | Individual direct stake; de facto controller together with Runze |
| Top institutional investors (Huaxia Fund, provincial vehicles) | ~8.5% | Mutual funds and insurance asset products; increased after 2024–2025 recovery |
| Post-IPO private equity / placements | Varied (minor dilution) | Focused on downstream API expansion; raised company valuation floor |
| Public float (retail shareholders) | Remainder (~52%) | Thousands of public shareholders introduced by the 2017 IPO |
The combined voting power of the Ma family and concerted parties exceeds 40%, preserving control against hostile takeovers; institutional and private equity stakes have grown in sophistication, driven by xylitol and erythritol export margin recovery and strategic API investments in 2024–2025.
Ownership Snapshot & Implications
Major shareholders concentrate control while institutions provide liquidity and valuation support after the 2017 IPO and 2024–2025 performance rebound.
- Founding family control via Runze and direct holdings exceeds 40%
- Top institutional investors hold ~8.5% collectively
- Private equity supports API expansion, slightly diluting founders but raising valuation
- Public float retains majority of free-float liquidity introduced in 2017
For detailed strategic analysis and historical context on the company’s investor relations and marketing moves, see Marketing Strategy of Shandong Sito Bio-technology
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Shandong Sito Bio-technology’s Board?
The Board of Directors of Shandong Sito Bio-technology is composed of nine members and is chaired by Ma Yantao; governance reflects concentrated ownership with the Ma family and Shandong Runze Investment exerting decisive control under a one-share-one-vote system.
| Director | Role / Background | Affiliation |
|---|---|---|
| Ma Yantao | Chairman; founder and controlling shareholder representative | Ma family / executive management |
| Liang Wei | CEO; operations and production oversight | Company executive |
| Wang Jun | CFO; finance and capital structure | Company executive |
| Independent Director 1 | Academic specialist in biochemistry; CSRC compliance | Shandong university |
| Independent Director 2 | Corporate law expert; governance oversight | Beijing law firm / legal academia |
| Independent Director 3 | Corporate finance academic; audit committee member | Beijing university |
| Shareholder Representative A | Investor relations and strategic partnerships | Shandong Runze Investment |
| Shareholder Representative B | Supply-chain and commercial strategy | Institutional investor |
| Non-executive Director | R&D and technology commercialization | Industry specialist |
Voting outcomes mirror ownership: the Ma family together with Shandong Runze Investment control a majority stake, leading to consistent approval rates above 95% at recent AGMs, including votes authorizing the 2025 amino acid production expansion; the board responded to investor concerns over share pledging by introducing transparency and pledge-reduction measures in late 2024.
Board Composition and Control
The board bridges family control and professional management, with three independent directors meeting CSRC norms and decisive voting by controlling shareholders.
- One-share-one-vote structure concentrates power with Ma family and Shandong Runze Investment
- Nine-member board includes three independent directors from Shandong and Beijing
- AGM approvals exceed 95% for major resolutions, including 2025 expansion
- Late 2024 transparency measures reduced share-pledge ratios to reassure markets
For governance context and market positioning, see Target Market of Shandong Sito Bio-technology.
Shandong Sito Bio-technology Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Shandong Sito Bio-technology’s Ownership Landscape?
From 2023 through early 2026 Shandong Sito Bio-technology ownership trended toward greater institutional participation driven by green-chemistry priorities and domestic supply-chain security, with strategic state-backed funds increasing their holdings after a 2024 secondary offering and 2025 buybacks modestly reducing outstanding shares.
| Year | Ownership Change | Key Figures |
|---|---|---|
| 2023 | Founder-led structure; low institutional stake | Institutional ownership: 10% |
| 2024 | Secondary offering for Bio-based Steroid Hormone API Project; state-backed funds buy majority of float | Raised capital: project-focused offering; retail float increased slightly |
| 2025 | Strategic share buybacks to support EPS; executive hires with equity incentives | Shares retired: ~1.5% |
| Early 2026 | Institutional ownership rises; succession discussions surface | Institutional ownership: ~16% |
State-aligned industrial funds and domestic pharmaceutical investors now represent a larger portion of Shandong Sito Bio-technology investors, while the Ma family retains controlling influence and seeks professionalization through hires from multinational pharma with small equity stakes.
Capital raise and strategic focus
The 2024 secondary raised targeted funding for the Bio-based Steroid Hormone API Project, aligning the company with China’s push for local pharmaceutical precursor production.
Institutional ownership trend
Institutional ownership climbed from 10% in 2023 to about 16% by early 2026, reflecting strategic purchases by state-backed funds.
Share buybacks and EPS
Buybacks in 2025 retired roughly 1.5% of outstanding shares to bolster earnings per share amid market volatility.
Leadership and succession
As Ma Yantao nears a decade of public leadership, market talk of succession and professionalization has increased, though no formal plan is public.
For background on the company’s origins and ownership history see Brief History of Shandong Sito Bio-technology
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Shandong Sito Bio-technology Company?
- What is Competitive Landscape of Shandong Sito Bio-technology Company?
- What is Growth Strategy and Future Prospects of Shandong Sito Bio-technology Company?
- How Does Shandong Sito Bio-technology Company Work?
- What is Sales and Marketing Strategy of Shandong Sito Bio-technology Company?
- What are Mission Vision & Core Values of Shandong Sito Bio-technology Company?
- What is Customer Demographics and Target Market of Shandong Sito Bio-technology Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.